1448717-51-8

Basic information

• Product Name: 2-{1-[3-(4-methoxy-phenyl)-azetidin-1-yl]-ethyl}-7-(tetrahydro-pyran-4-yl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one
• Synonyms: 2-{1-[3-(4-methoxy-phenyl)-azetidin-1-yl]-ethyl}-7-(tetrahydro-pyran-4-yl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one
• CAS NO: 1448717-51-8
• Molecular Weight: 409.488
• Mol File: 1448717-51-8.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-{1-[3-(4-methoxy-phenyl)-azetidin-1-yl]-ethyl}-7-(tetrahydro-pyran-4-yl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-{1-[3-(4-methoxy-phenyl)-azetidin-1-yl]-ethyl}-7-(tetrahydro-pyran-4-yl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one(1448717-51-8)
• EPA Substance Registry System: 2-{1-[3-(4-methoxy-phenyl)-azetidin-1-yl]-ethyl}-7-(tetrahydro-pyran-4-yl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one(1448717-51-8)

Safety Data

• Hazardous Substances Data: 1448717-51-8(Hazardous Substances Data)

Upstream product

• 7215-07-8 3-(4-methoxy-phenyl)-azetidine 
• 1448718-29-3 2-acetyl-7-(tetrahydro-pyran-4-yl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one 
• 1448718-28-2 2-(1-hydroxy-ethyl)-7-(tetrahydro-pyran-4-yl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one 
• 1448718-27-1 2-(1-benzyloxy-ethyl)-7-(3,6-dihydro-2H-pyran-4-yl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one 
• 1448718-26-0 2-(1-benzyloxy-ethyl)-7-iodo-3H-imidazo[5,1-f][1,2,4]triazin-4-one 
• 1448718-25-9 2-(1-benzyloxy-ethyl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one 
• 1448718-24-8 3-(2-benzyloxy-propionylamino)-3H-imidazole-4-carboxylic acid amide 
• 1448718-23-7 3-(2-benzyloxy-propionylamino)-3H-imidazole-4-carboxylic acid methyl ester 

Downstream Products

• 1448717-52-9 2-{1-[3-(4-methoxy-phenyl)-azetidin-1-yl]-ethyl}-7-(tetrahydro-pyran-4-yl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one 
• 1448717-53-0 2-[(1R)-1-[3-(4-methoxyphenyl)azetidin-1-yl]ethyl]-7-tetrahydropyran-4-yl-3H-imidazo[5,1-f][1,2,4]triazin-4-one 

Relevant articles and documents

PDE9 inhibitors with imidazo triazinone backbone

This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).